GLP-1 drugs are best known for helping people manage diabetes and lose weight, but researchers are increasingly asking if their effects extend into other areas of health. A large new study involving more than 100,000 women found that those who had been prescribed GLP-1 medications had a lower rate of breast cancer than women who had not used the drugs.
The association remained after researchers matched women for several factors that can influence breast cancer risk, including age, body mass index, breast density and type 2 diabetes.
The finding is attention-grabbing, but it needs an important qualification. This was an observational study. It cannot prove that GLP-1 medications prevent breast cancer or that taking one will lower an individual woman’s cancer risk.
Researchers studied more than 111,000 women
The researchers examined electronic health records from women who underwent breast imaging between January 2022 and June 2025. They narrowed the analysis to 111,646 women ages 45 to 80 who had a BMI of at least 25 and a documented breast-imaging outcome.
The study included women who had and had not been prescribed GLP-1 receptor agonists before their breast examination. The median age of the women included was 61.
Among the full group, 15,264 women had prior GLP-1 exposure, while 96,382 had not. Researchers identified 2,628 breast cancer cases in total during the study period.
The researchers were particularly interested in GLP-1 medications because excess body weight is an established breast cancer risk factor, and these drugs can produce substantial weight loss while also changing metabolic health.
Takeaway: The study was large enough to compare breast cancer diagnoses between thousands of GLP-1 users and a much larger group of women who had not used the drugs.
Breast cancer was less common among GLP-1 users
In the full group, breast cancer was diagnosed in 1.62% of women who had GLP-1 exposure compared with 2.47% of women who had not been exposed to the medications.
The researchers calculated an odds ratio of 0.649 for breast cancer among GLP-1 users. That represents substantially lower odds of being diagnosed with breast cancer in the exposed group, but it does not prove that the medication itself caused the difference.
Women who use GLP-1 medications can differ from nonusers in many ways, including diabetes status, weight, access to health care and other health behaviors. Those differences can influence cancer risk independently of the medication.
That is why the researchers performed another analysis designed to make the two groups more comparable.
Takeaway: Breast cancer diagnoses were less frequent among women with GLP-1 exposure, but the raw comparison alone could not explain why.
The association remained after researchers matched the groups
To reduce some of the differences between GLP-1 users and nonusers, researchers matched women according to age, race, ethnicity, BMI, breast density and history of type 2 diabetes.
The matched analysis included 30,528 observations and 600 breast cancer cases. Even after that matching, GLP-1 exposure was still associated with lower breast cancer incidence, with an odds ratio of 0.695.
In simple terms, the association did not disappear after several major risk-related characteristics were made more comparable between the groups.
That strengthens the finding, but it does not turn the study into a randomized clinical trial. Other differences that researchers did not measure could still help explain the result.
Related: Six simple health checks that can reveal important warning signs early
Save this article
Enter your email address and we'll send it straight to your inbox.
Takeaway: Matching women on several important characteristics reduced some obvious sources of bias, and the lower breast cancer rate among GLP-1 users remained.
Weight loss could be part of the explanation
One possible explanation involves body weight itself. Excess weight, particularly later in life, is associated with increased breast cancer risk, and GLP-1 drugs can help many patients lose a meaningful amount of weight.
The drugs also affect blood sugar, insulin signaling and other metabolic processes. Researchers are interested in the possibility that some of these changes could influence biological pathways involved in cancer development.
But the study was not designed to show which mechanism, if any, produced the lower breast cancer incidence. It also could not determine that weight loss was responsible for the association.
The relationship may involve weight reduction, metabolic changes, differences between patients who receive GLP-1 therapy or a combination of factors that researchers have not yet identified.
Takeaway: There are plausible reasons GLP-1 treatment could be connected with breast cancer risk, but this study cannot establish the biological explanation.
This does not mean GLP-1 drugs prevent breast cancer
The most important limitation is the study design. Researchers looked backward at medical records and compared outcomes among women who had already been prescribed GLP-1 medications with those who had not. They did not randomly assign women to take the drugs and then follow them for cancer prevention.
That means the results show association, not causation.
The study also focused on women with overweight or obesity who underwent breast imaging at a major academic medical center and affiliated sites. The findings may not apply in exactly the same way to every woman or every population.
Researchers themselves concluded that prospective trials are needed to examine GLP-1 agonists specifically in relation to breast cancer prevention.
For now, GLP-1 medications should not be viewed as breast cancer prevention drugs based on this research alone.
Takeaway: The study provides a reason for more research, not evidence that women should take GLP-1 medications to prevent breast cancer.
The finding could open a much bigger research question
GLP-1 medications are now being studied far beyond their original use in diabetes. As millions of people take them for diabetes and obesity, researchers have an opportunity to examine how the drugs may relate to cardiovascular disease, kidney health, neurological conditions and cancer.
Breast cancer is particularly important because body weight and metabolic health can influence risk, especially after menopause. A medication capable of producing major changes in both could plausibly affect cancer outcomes, but that possibility needs to be tested directly.
The current study gives researchers a strong signal to investigate. The next step is determining if the association holds up in prospective studies and, if it does, why.
For women already taking GLP-1 medications for approved medical reasons, the findings may be encouraging. They should not be interpreted as a reason to start treatment solely because of breast cancer concerns.
Question for you. Would evidence that GLP-1 drugs affect long-term cancer risk change how you think about these medications?
